TREATMENT SOLUTION FOR TREATING WOUNDS, IN PARTICULAR FOR LIQUID WOUND TREATMENT

The invention relates to a treatment solution for treating wounds, preferably for liquid wound treatment of acute and chronic wounds, made of an aqueous solution including zinc, iron, and acid, wherein the per liter proportion of zinc is 10 to 100 mg, the proportion of iron is 6.5 to 60 mg, and the proportion of acid is selected such that the pH value of the treatment solution is 2.5 to 3.5.

Skip to: Description  ·  Claims  · Patent History  ·  Patent History
Description
BACKGROUND OF THE INVENTION

The invention relates to a treatment solution and in particular to a treatment solution for liquid wound treatment, in which the wound to be treated is maintained in a liquid state with a sufficiently large volume of treatment liquid. This treatment results in accelerated wound healing with optimized scar formation.

A treatment solution for liquid wound treatment is known in the art (DE 101 39 398 A1). The known treatment solution consists of an aqueous solution comprising zinc in the form of ZnCl2, iron in the form of FeSO4 and an inorganic acid in such proportions that the solution contains 10-100 mg of zinc and 6.5-65 mg of iron per liter of liquid and the pH value of the solution is regulated to a value between 2.5 and 3.5.

It has been shown that the prior treatment solution achieves very good results in the treatment of postoperative wounds, such results cannot be determined for wound treatment in general, especially not for the treatment of acute and chronic wounds.

It is an object of the invention is to present a treatment solution which achieves optimal treatment results in general for the treatment of acute and chronic wounds, i.e. fast wound healing with optimal scar formation.

SUMMARY OF THE INVENTION

The treatment solution according to the invention is especially suitable for treating

  • skin lacerations
  • cuts and abrasions, as well as lacerated wounds
  • decubital ulcers
  • arterio-venous ulcers
  • diabetic ulcers
  • 1st and 2nd degree burns
  • for moistening bandages and wound dressings, such as compresses, gauze, sponges, alginates, etc.; when changing bandages, for dissolving encrusted bandages or other encrusted wound dressings.

The treatment solution according to the invention consists of an aqueous solution comprising in addition to zinc and iron, at least one tenside, for example cocamidopropyl betaine, and an antiseptic component in the form of polyhexanide, preferably in the form of PHMB or polyaminopropyl biguanide.

DETAILED DESCRIPTION OF THE INVENTION

The components of the treatment solution, according to the invention, support each other in a synergetic manner, so that the liquid wound treatment solution can be used for acute and chronic wounds and achieves the desired results.

The special composition of the treatment solution, according to the invention, causes a synergetic effect of the components during the treatment of the respective wound in such a manner that first, due to the tenside contained in the solution, protein components, necrotic tissue components, etc. are removed from the wound, so that then in a second stage the antiseptic component can become fully effective for the initial destruction of germs present in the wound, so that then the prerequisites conducive to healing of the wound by the metal ions (iron and zinc) are created and that the respective wound can be kept free of germs by the metal ions during the liquid treatment.

Generally, the treatment solution according to the invention contains the following proportions of the components per liter of solution (especially water):

tenside: 1000-6000 mg

antiseptic component,

in particular polyhexanide: 100-1000 mg

zinc: 10-100 mg

iron: 6.5-60 mg

In a preferred embodiment, the treatment solution contains the following proportions of the components per liter of solution (especially water):

tenside: ca. 3000 mg

antiseptic component,

for example polyhexanide: ca. 200 mg

zinc: 15-45 mg

iron: 10-30 mg.

By adding an acid, preferably an inorganic acid, e.g. by adding hydrochloric acid, the pH value of the treatment solution is regulated to a value between 2.5 and 3.5, preferably to a value between 2.75 and 3.5.

Claims

1. A treatment solution for liquid wound treatment of acute and chronic wounds, consisting essentially of an aqueous solution containing at least zinc, iron and acid, wherein a per liter proportion of zinc is from 10-100 mg per liter of solution, a proportion of iron is from 6.5-60 mg per liter of solution and a proportion of the acid is selected such that a pH value of the treatment solution is between 2.5 and 3.5, wherein the treatment solution additionally contains a tenside and an antiseptic component, and a per liter proportion of the tenside is from 1000-6000 mg per liter of solution and a proportion of the antiseptic component is from 100-1000 mg per liter of solution.

2. The treatment solution according to claim 1, wherein the tenside is cocamidopropyl betaine.

3. The treatment solution according to claim 1, wherein the antiseptic component is polyhexanide or polyaminopropyl biguanide.

4. The treatment solution according to claim 1, wherein the proportion of zinc is from 15-45 mg per liter of solutions and the proportion of iron is from 10-30 mg per liter of solution.

5. The treatment solution according to claim 1, wherein the pH value is between 2.75 and 3.5.

6. The treatment solution according to claim 1, wherein the proportion of the tenside is 3000 mg per liter of solution.

7. The treatment solution according to claim 1, wherein the proportion of the antiseptic component is 200 mg per liter of solution.

8. A treatment solution consisting essentially of the following proportions of components per liter of solution:

from 10-100 mg of zinc;
from 6.5-60 mg of iron;
from 1000-6000 mg of a tenside; and
from 100-1000 mg of an antiseptic component.

9. A treatment solution consisting essentially of the following proportions of the components per liter of solution:

from 15-45 mg of zinc;
from 10-30 mg of iron;
3000 mg of tenside; and
200 mg of an antiseptic component.
Patent History
Publication number: 20110318428
Type: Application
Filed: Feb 5, 2010
Publication Date: Dec 29, 2011
Patent Grant number: 8846109
Inventor: Thomas Riesinger (Nurnberg)
Application Number: 13/148,406
Classifications
Current U.S. Class: For Topical Application (424/642)
International Classification: A61K 33/30 (20060101); A61P 17/02 (20060101);